GlassScriptPhysician profile
Harley Jacob Davis
NPI 1225697030
$6,429.59
in general payments reported to CMS, 2019-2025
27 companies · $871 in 2025
The $871 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $82.17 · 2021: $813 · 2022: $1,843 · 2023: $1,532 · 2024: $1,288 · 2025: $871.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,258 · Education: $434.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,257.93 |
| Education | $433.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,037.61 | 2021-2025 | Rinvoq, Skyrizi |
| Genzyme Corporation | $980.12 | 2020-2025 | |
| Janssen Biotech, INC. | $720.16 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $571.45 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $544.91 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Galderma Laboratories, L.P. | $357.55 | 2021-2024 | Aklief, Epsolay, Oracea |
| Amgen INC. | $356.84 | 2022-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $353.43 | 2021-2025 | Dupixent |
| Ucb, INC. | $304.38 | 2022-2025 | Bimzelx, Cimzia |
| Incyte Corporation | $239.73 | 2022-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $176.11 | 2020-2024 | |
| Pfizer INC. | $145.26 | 2022-2025 | |
| Kyowa Kirin, INC. | $95.71 | 2022 | |
| Sun Pharmaceutical Industries INC. | $85.38 | 2021 | |
| Leo Pharma INC. | $84.30 | 2022-2023 | Adbry |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $71.82 | 2023-2024 | Vtama |
| Almirall LLC | $59.97 | 2022-2025 | Klisyri, Seysara |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $36.55 | 2023-2024 | Jublia, Arazlo, Cabtreo |
| Mayne Pharma Commercial LLC | $35.61 | 2023-2024 | |
| Arcutis Biotherapeutics, INC. | $35.41 | 2024 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.71 | 2023 | Spevigo |
| Genentech USA, INC. | $21.15 | 2021 | |
| Journey Medical Corporation | $20.57 | 2024 | |
| Botanix Sb INC | $19.42 | 2025 | Sofdra |
| Organon LLC | $17.77 | 2025 | Vtama |
| Ani Pharmaceuticals, INC. | $16.97 | 2023 | Apexicon E |
| Medimetriks Pharmaceuticals, INC. | $13.70 | 2025 | Neo-Synalar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harley Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.